Supporting the concept that malignant tumors ultimately develop resistance to therapy with a VEGF inhibitor, two recent studies (one of which included a xenograft mouse model of GBM) suggested that treatment with a VEGF inhibitor alters the natural history of the tumor and promotes a highly invasive and metastatic phenotype [138, 139]. This evidence concerns the gene VEGFA and cancer.